Salivary gland

Head and Neck Squamous Cell Carcinoma Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 2, 2021
Health, Biotechnology, Cancer, Head, EGFR, Diagnosis, History, Pharynx, C09, HNC, Epidemiology, Radiation, AGR, Histology, Tobacco smoking, Profile, Salivary gland, ICD-10, Organizing, Risk, C10, Mouth, Method, Organic acid, Therapy, CPS, C32, Population, Squamous cell carcinoma, Dietary supplement, Management, Pharmaceutical industry, Medical imaging, Dentistry, Mobile phone

The "Head and Neck Squamous Cell Carcinoma - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Head and Neck Squamous Cell Carcinoma - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • In the 8MM, the diagnosed incident cases of HNC are expected to increase from 279,734 cases in 2020 to 338,790 cases in 2030, at an Annual Growth Rate (AGR) of 2.11%.
  • In 2030, urban China will have the highest number of diagnosed incident cases of HNC in the 8MM, with 141,960 diagnosed incident cases, whereas Italy will have the fewest diagnosed incident cases with 13,720 cases.
  • The report provides a 10-year epidemiological forecast of the diagnosed incident cases of HNCs.

Salivary Bioscience Studies That Have Impact: Getting Back to Our ABCDs

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Anatomy, Organ systems, Salivary gland pathology, Exocrine system, Saliva, Salivary gland, ABCD Study, Sjögren syndrome, Clinical Laboratory Improvement Amendments, Assay, Saliva testing

"\nAlthough COVID-19 has dominated much of the story of saliva over the last year, the ABCD study is a reminder that Salivary Bioscience makes a positive impact outside of COVID-19.

Key Points: 
  • "\nAlthough COVID-19 has dominated much of the story of saliva over the last year, the ABCD study is a reminder that Salivary Bioscience makes a positive impact outside of COVID-19.
  • Baseline data, such as the association between body mass index and hormone levels, has already been generated from this study.
  • "Salimetrics is ready with the experience and the latest knowledge in salivary bioscience," says Dr. Gaitonde.
  • "\nSalimetrics\' assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health and immune function.

MeiraGTx Announces Participation at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 5, 2021
Branches of biology, Health sciences, Organ systems, Saliva, XC2, Xerostomia, Salivary gland, Sjögren syndrome, Therapy, Neurodegeneration, Retina

b'LONDON\xc2\xa0and\xc2\xa0NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings\xc2\xa0plc\xc2\xa0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\xc2\xa0Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multiple conferences in May.\nLive webcasts of the presentations (where applicable) will be on the Investors page of the Company\xe2\x80\x99s website at www.investors.meiragtx.com .

Key Points: 
  • b'LONDON\xc2\xa0and\xc2\xa0NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings\xc2\xa0plc\xc2\xa0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\xc2\xa0Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multiple conferences in May.\nLive webcasts of the presentations (where applicable) will be on the Investors page of the Company\xe2\x80\x99s website at www.investors.meiragtx.com .
  • Led by an experienced management team,\xc2\xa0MeiraGTx\xc2\xa0has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications.
  • MeiraGTx\xe2\x80\x99s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia.
  • Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.\n'

MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit

Retrieved on: 
Monday, April 19, 2021
Branches of biology, Biology, Medicine, Saliva, XC2, Xerostomia, Sjögren syndrome, Salivary gland, Gene therapy

b'LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings\xc2\xa0plc\xc2\xa0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\xc2\xa0Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief development officer, will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on Monday, April 26, 2021 at 1:45 p.m. ET.\nA live webcast of the presentation will be available on the Investors page of the Company\xe2\x80\x99s website at www.investors.meiragtx.com .

Key Points: 
  • b'LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings\xc2\xa0plc\xc2\xa0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\xc2\xa0Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief development officer, will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on Monday, April 26, 2021 at 1:45 p.m. ET.\nA live webcast of the presentation will be available on the Investors page of the Company\xe2\x80\x99s website at www.investors.meiragtx.com .
  • Led by an experienced management team,\xc2\xa0MeiraGTx\xc2\xa0has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications.
  • MeiraGTx\xe2\x80\x99s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia.
  • Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.\n'

Saliva-Based Hormone Monitoring for IVF: New Data Presents High Patient Serum-Saliva Correlations for Estradiol

Retrieved on: 
Wednesday, March 3, 2021
Branches of biology, Articles, Biology, Fertility medicine, Human pregnancy, Fertility, Obstetrics, Reproduction, In vitro fertilisation, Salivary gland, Assisted reproductive technology, Estradiol

Results from this blind validation study suggest that saliva-based hormone tests have the capacity to become the preferred method of hormone monitoring for fertility treatments in the future.

Key Points: 
  • Results from this blind validation study suggest that saliva-based hormone tests have the capacity to become the preferred method of hormone monitoring for fertility treatments in the future.
  • This research further echoes similar results from previous studies that have also shown good agreement between serum-saliva oestradiol levels.
  • For most couples and individuals, In Vitro Fertilization (IVF) often represents a physically and emotionally painful process.
  • Samples were evaluated for salivary oestradiol, with resulting saliva-serum correlations ranging from 0.68 in two European clinics, up to 0.87 and 0.91 in two US clinics.

INTRODUCING ALT: ADVANCED LIQUID TECHNOLOGY CANNABIS

Retrieved on: 
Wednesday, December 16, 2020
Cannabis smoking, Herbalism, Medicinal plants, Branches of biology, Psychoactive drugs, Health sciences, Cannabis, Entheogens, Medical cannabis, Effects of cannabis, Salivary gland, Edible

Los Angeles, CA, Dec. 16, 2020 (GLOBE NEWSWIRE) -- ALT (Advanced Liquid Technology) fuses nature with science to create the first highly adaptable liquid cannabis beverage enhancement that can be added to any drink for a truly customizable experience.

Key Points: 
  • Los Angeles, CA, Dec. 16, 2020 (GLOBE NEWSWIRE) -- ALT (Advanced Liquid Technology) fuses nature with science to create the first highly adaptable liquid cannabis beverage enhancement that can be added to any drink for a truly customizable experience.
  • Available in 5mg and 10mg formulations, ALTs unique sugar-free liquid is designed to offer all the benefits of cannabis without the common drawbacks of other delivery methods, such as the delayed onset that occurs with edibles and the health risks of smokable cannabis like joints and vapes.
  • ALTs liquid delivery method allows for faster onset and offset through the salivary glands, before traveling through the digestive tract.
  • Using nanotechnology, the particle size of cannabis is decreased, leading to faster and more effective absorption into the body.

Another Salivary Bioscience Breakthrough: Research Study Obtains 100% Sensitivity and Specificity for COVID-19 Serology with Support from Salimetrics

Retrieved on: 
Tuesday, November 24, 2020
Branches of biology, Anatomy, Exocrine system, Saliva, Salivary gland, Coronavirus disease, Organ systems

The significance of this COVID-19 serology study was featured recently in a news release from the Johns Hopkins Bloomberg School of Public Health .

Key Points: 
  • The significance of this COVID-19 serology study was featured recently in a news release from the Johns Hopkins Bloomberg School of Public Health .
  • "We've supported over 20,000 studies, and that experience has put Salimetrics at the leading edge of salivary bioscience methods.
  • This study illustrates that saliva, and how to collect it right, can facilitate widespread, scalable surveillance with uncompromised sensitivity and specificity through practical, non-invasive sampling.
  • "Supported with key scientific knowledge from Salimetrics, this study provides one more step to enable future research and application."

MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit

Retrieved on: 
Tuesday, November 10, 2020
Branches of biology, Life sciences, Biology, Biotechnology, Applied genetics, Gene therapy, Molecular biology, Therapy, Salivary gland, Spark Therapeutics

LONDONandNEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdingsplc(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced thatAlexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Monday, November 16, 2020 at 1:30 p.m.

Key Points: 
  • LONDONandNEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdingsplc(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced thatAlexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Monday, November 16, 2020 at 1:30 p.m.
  • A live webcast of the presentation will be available on the Investors page of the Companys website at www.investors.meiragtx.com .
  • MeiraGTx(Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs.MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology.
  • Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

Devoted to Salivary Bioscience: International Journal of Behavioral Medicine Publishes First Special Issue Focused on Saliva-Based Research

Retrieved on: 
Monday, June 15, 2020
Branches of biology, Academic journals, Enzymes, Periodicals, Alpha-amylase, Salivary gland, Behavioral medicine, Journal of Behavioral Medicine, Amylase, Saliva, Saliva testing

Recently, the field has passed several milestones, including saliva-based assays for COVID-19, the release of a foundational reference guide, " Salivary Bioscience Foundations of Interdisciplinary Saliva Research and Applications ", and the first special issue of an international journal devoted to Salivary Bisocience from the IJBM.

Key Points: 
  • Recently, the field has passed several milestones, including saliva-based assays for COVID-19, the release of a foundational reference guide, " Salivary Bioscience Foundations of Interdisciplinary Saliva Research and Applications ", and the first special issue of an international journal devoted to Salivary Bisocience from the IJBM.
  • The International Journal of Behavioral Medicine (IJBM) is the official scientific journal of the International Society for Behavioral Medicine (ISBM) which aims to present the best theoretically driven, evidence-based work in the field of behavioral medicine from around the globe.
  • The special issue also features an overview of the use of salivary measures in behavioral medicine with original salivary bioscience studies, reviews of two prominent salivary markers (estradiol and alpha-amylase), and guidance on the physiometrics of salivary data.
  • Researchers can Contact Salimetrics for more information or review the International Journal for Behavioral Medicine Special Issue on the Springer Website.

Metabolic Insights Inc. Awarded $300,000 by NRC-IRAP to Develop a Prototype Point-of-Care COVID-19 Virus Test

Retrieved on: 
Saturday, June 6, 2020
Medicine, RTT, Organ systems, Clinical medicine, Saliva testing, IRAP, Insulin, Salivary gland, Saliva, Sjögren syndrome

The funds will be used to re-purpose the Company's existing proprietary salivary insulin technology to detect the SARS-2-CoV(COVID-19) virus in saliva.

Key Points: 
  • The funds will be used to re-purpose the Company's existing proprietary salivary insulin technology to detect the SARS-2-CoV(COVID-19) virus in saliva.
  • One of theobjectives of the challenge is to demonstrate a new prototype point-of-care COVID-19 test in three months.
  • "We built our technology platform to allow for the testing of a variety of proteins through a simple saliva test.
  • The mission of NRC-IRAP is to accelerate businesses by providing them with a comprehensive suite of innovation services and funding.